Pluristem Therapeutics Shares Slump A Day Before Phase 1/2 Study Results Are Released

Published: Jan 20, 2014

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

The share price of Pluristem Therapeutics Ltd. (Nasdaq:PSTI; TASE: PLTR) fell by 19.5% in morning trading on the Tel Aviv Stock Exchange (TASE) today, before partly recovering, without any announcement from the company. The volatility in share price comes a day before the company publishes the results of a clinical trial of its stem cell treatment for muscle injury. Pluristem's share price was down 8.3% by early afternoon on the TASE today, to NIS 14.42, after falling 0.9% on Nasdaq on Friday to $4.43, giving a market cap of $265 million.

Help employers find you! Check out all the jobs and post your resume.

Back to news